145 related articles for article (PubMed ID: 16363577)
1. [PPI plus bismuth-based quintuple therapy].
Kimura K; Hiratsuka T; Tamura K; Hiratsuka H; Suzuki T; Bray R
Nihon Rinsho; 2005 Nov; 63 Suppl 11():452-8. PubMed ID: 16363577
[No Abstract] [Full Text] [Related]
2. [Anti-Helicobacter pylori quadruple therapy].
Fukuda Y; Sakagami T
Nihon Rinsho; 2005 Nov; 63 Suppl 11():442-51. PubMed ID: 16363576
[No Abstract] [Full Text] [Related]
3. [Adverse effects of Helicobacter pylori eradication and its prevention].
Zhang S; Yanaka A
Nihon Rinsho; 2005 Nov; 63 Suppl 11():414-7. PubMed ID: 16363570
[No Abstract] [Full Text] [Related]
4. [Comparison between one-week and two-week regimens of new triple therapy in H. pylori eradication].
Kobayashi K; Fujishiro M; Omata M; Oka M
Nihon Rinsho; 2005 Nov; 63 Suppl 11():459-60. PubMed ID: 16363578
[No Abstract] [Full Text] [Related]
5. [Helicobacter pylori eradication therapy for children].
Konno M
Nihon Rinsho; 2005 Nov; 63 Suppl 11():470-3. PubMed ID: 16363581
[No Abstract] [Full Text] [Related]
6. Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Fennerty MB
Am J Gastroenterol; 1998 Jan; 93(1):2-3. PubMed ID: 9448162
[No Abstract] [Full Text] [Related]
7. [Second-line eradication therapy for H. pylori infection--PPI+AMPC+MNZ triple therapy].
Okimoto T; Murakami K; Fujioka T
Nihon Rinsho; 2005 Nov; 63 Suppl 11():435-7. PubMed ID: 16363574
[No Abstract] [Full Text] [Related]
8. [Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?].
Nagahara A; Sato N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():421-5. PubMed ID: 16363572
[No Abstract] [Full Text] [Related]
9. [Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment].
Tsukada K; Katoh H; Miyazaki T; Kuwano H
Nihon Rinsho; 2005 Nov; 63 Suppl 11():486-8. PubMed ID: 16363585
[No Abstract] [Full Text] [Related]
10. [Triple therapy with faropenem, proton pump inhibitor (PPI), and amoxicillin for clarithromycin-resistant H. pylori eradication].
Mitsuno Y; Yoshida H
Nihon Rinsho; 2002 Feb; 60 Suppl 2():452-4. PubMed ID: 11979826
[No Abstract] [Full Text] [Related]
11. [Triple therapy for eradication of Helicobacter pylori in Japan].
Takeda H
Nihon Rinsho; 2005 Nov; 63 Suppl 11():409-13. PubMed ID: 16363569
[No Abstract] [Full Text] [Related]
12. [Guidelines in the management of H. pylori infection in Japan].
Asaka M
Nihon Rinsho; 2005 Nov; 63 Suppl 11():12-6. PubMed ID: 16363496
[No Abstract] [Full Text] [Related]
13. [Eradication therapy for clarithromycin-resistant and metronidazole-resistant Helicobacter pylori infection].
Inoue K; Sugano K
Nihon Rinsho; 2002 Feb; 60 Suppl 2():460-4. PubMed ID: 11979828
[No Abstract] [Full Text] [Related]
14. [H. pylori eradication package set (Lansap)].
Kawai T; Kawakami K; Moriyasu F; Takagi Y
Nihon Rinsho; 2005 Nov; 63 Suppl 11():361-5. PubMed ID: 16363560
[No Abstract] [Full Text] [Related]
15. [Ecabet sodium (ECA) + PPI + AMPC therapy for clarithromycin-resistant Helicobacter pylori infections].
Kagaya H; Kato M; Asaka M
Nihon Rinsho; 2002 Feb; 60 Suppl 2():455-9. PubMed ID: 11979827
[No Abstract] [Full Text] [Related]
16. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
Mégraud F; Malfertheiner P
Helicobacter; 1996 Jun; 1(2):118-21. PubMed ID: 9398889
[No Abstract] [Full Text] [Related]
18. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Laine L; Estrada R; Trujillo M; Emami S
Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
[TBL] [Abstract][Full Text] [Related]
19. [Second line treatment regimen of PPI + AMPC + MNZ for patients with clarithromycin-resistant Helicobacter pylori infection].
Tokunaga K; Takahashi S
Nihon Rinsho; 2002 Feb; 60 Suppl 2():445-8. PubMed ID: 11979824
[No Abstract] [Full Text] [Related]
20. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
Lara LF; Cisneros G; Gurney M; Van Ness M; Jarjoura D; Moauro B; Polen A; Rutecki G; Whittier F
Arch Intern Med; 2003 Sep; 163(17):2079-84. PubMed ID: 14504122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
